Document Classification

Section Type: RESULTS

Text: In comparison with placebo, GFT505 significantly reduced fasting plasma triglycerides (S1 : least squares means -16. 7 % [95 % one-sided CI - to -5. 3], P = 0. 005 ; S2 : -24. 8 % [- to -10. 5], P = 0. 0003) and increased HDL cholesterol (S1 : 7. 8 % [3. 0 to], P = 0. 004 ; S2 : 9. 3 % [1. 7 to], P = 0. 009) in both studies, whereas LDL cholesterol only decreased in S2 (-11. 0 % [- to -3. 5], P = 0. 002).